BioMedNewsBreaks

TuesdayApr 06, 2021 11:00 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Initiates Phase 2 RESERVOIR Trial for Treatment of COVID-19 GI Infections

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide (“FW-1022”) for the treatment of COVID-19-related gastrointestinal (GI) infections. Patient enrollment is expected to begin in April 2021 with topline data anticipated in the first quarter of 2022. “Initiation of the Phase 2 clinical trial of FW-1022 for the treatment of COVID-19 GI infection, or the RESERVOIR trial, is a significant milestone for AzurRx and an important advance in the…

Continue Reading

MondayApr 05, 2021 1:48 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Poised Amid Demand for Rapid Testing Kits

United Medical Equipment (“UME,” “UMEBSNI”), a company offering rapid COVID-19 testing kits, looks positioned to benefit from the high demand for its products. The demand arises from expert recommendations that identifying those infected through rapid testing could help curb the virus and prevent the emergence of new variants. An article about these developments reads, “‘Testing is actually more important now than it was eight months ago because of the high contagiousness rate of these new variants,’ Mara Aspinall, a professor of health practice at Arizona State University, said in a recent interview for NPR. ‘It is critical to stop these…

Continue Reading

MondayApr 05, 2021 12:18 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming Virtual Cell & Gene Meeting on the Mediterranean

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced that its COO and Executive VP, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean. The event is slated to take place virtually from April 6-9, 2021, with company presentations available for on-demand viewing throughout the entirety of the conference. Organized by the Alliance for Regenerative Medicine, the four-day virtual conference will feature more than 80 dedicated company presentations by leading public and private companies, highlighting recent technical and clinical achievements in the areas…

Continue Reading

ThursdayApr 01, 2021 12:24 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Key Results from Phase 2b OPTION 2 Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared key takeaways from its topline results on its Phase 2b OPTION 2 clinical trial. The trial studied AzurRx’s drug candidate MS1819 in the treatment of cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The trial results were shared during a March 31, 2021, conference call hosted by AzurRx president, CEO and chair James Sapirstein and AzurRx chief medical…

Continue Reading

ThursdayApr 01, 2021 10:33 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Reports Update in Shareholder Letter

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has provided a corporate update in a shareholder letter from LexaGene CEO and founder Dr. Jack Regan. In the letter, Regan reported that the company had crossed a major milestone by securing a sales contract in both the drug and vaccine manufacturing market and in the veterinary medicine space; both sales were the result of successful technology demonstrations, the letter noted. The company has also focused on ensuring consistency in microfluidic operations across MiQLab(TM) systems, Regan observed, noting that expectations have now been…

Continue Reading

TuesdayMar 30, 2021 2:33 pm

BioMedNewsBreaks – BioSig Technologies Inc. (NASDAQ: BSGM) Awarded U.S. Patent Claims for PURE EP(TM) Noise-Filtering Technology

BioSig Technologies (NASDAQ: BSGM), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent covering its PURE EP(TM) noise-filtering technology. According to the update, the recently allowed patent application number 17/082,564, entitled, “SYSTEMS AND METHODS FOR PERFORMING ELECTROPHYSIOLOGY (‘EP’) SIGNAL PROCESSING " was filed on October 28, 2020. "We are pleased to announce this newest patent allowance, which demonstrates the clinical significance of our PURE EP(TM) System in filtering noise from complex cardiac…

Continue Reading

TuesdayMar 30, 2021 12:25 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell lung cancer (“NSCLC”), will be featured in two presentations at the upcoming annual meeting of the American Association for Cancer Research (“AACR 21”). The event is slated to take place virtually from April 9-14, 2021. “We look forward to the presentation of these data that…

Continue Reading

TuesdayMar 30, 2021 11:39 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils New MyoCorrect Orofacial Myofunctional Therapy Service

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has announced a new service called MyoCorrect. The exclusive training provides therapists with access to orofacial myofunctional therapy (“OMT”) via telemedicine technology using the company’s Vivos System. Vivos anticipates this new service will provide increased revenue through With this new training, Vivos expects to see additional revenue through increased cases and fees. The company expects its MyoCorrect service will become an effective treatment of OSA, thereby giving Vivos an additional competitive advantage in the OSA treatment…

Continue Reading

TuesdayMar 30, 2021 11:04 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Multi-Omic Approach to New Drug Discovery

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. Predictive Oncology is confident that a multi-omic approach offers a much greater ability for success. The company is a leader in this area where few comprehensive, multi-omic datasets exist, especially in cancer, and such data is difficult to quickly access, as well as costly and…

Continue Reading

MondayMar 29, 2021 3:29 pm

BioMedNewsBreaks – Healthtech Solutions Inc.’s (HLTT) Medi-Scan Featured in BioWorld(TM) Article

Healthtech Solutions’ (OTC: HLTT) subsidiary, Medi-Scan Inc., was featured in a recent BioWorld(TM) article titled, “Medi-Scan’s digital tool converts ultrasound images to 3D at the point of care.” The piece discusses Medi-Scan’s cloud-based software that has the capability to rapidly (in less than two minutes) convert the data on ultrasound analog 2D grayscale images into a digital 3D high-definition (“HD”) format. The company’s efforts currently focus on the heart and lungs, as it aims to provide quick, point-of-service evaluation and triaging of patients with heart disease and other conditions, including those suffering from COVID-19. Medi-Scan’s machine learning-based solution provides clinicians…

Continue Reading